Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands was written by Mach, Ulrich R.;Hackling, Anneke E.;Perachon, Sylvie;Ferry, Sandrine;Wermuth, Camille G.;Schwartz, Jean-Charles;Sokoloff, Pierre;Stark, Holger. And the article was included in ChemBioChem in 2004.SDS of cas: 52250-50-7 This article mentions the following:
Based on N-alkylated 1,2,3,4-tetrahydroisoquinoline derivatives which are structurally related to the partial agonist BP 897, a series of novel, selective dopamine D3 receptor antagonists has been synthesized. Derivatization included changes in the arylamide moiety and the tetrahydroisoquinoline substructure leading to compounds with markedly improved selectivities and affinities in the low nanomolar concentration range. From the 55 structures presented here, (E)-3-(4-iodophenyl)-N-(4-(1,2,3,4-tetrahydroisoquinolin-2-yl)butyl)acrylamide (51) has high affinity (Ki(hD3) = 12 nM) and a 123-fold preference for the D3 receptor relative to the D2 receptor subtype. Its pharmacol. profile offers the prospect of a novel radioligand as a tool for various dopamine D3-receptor-related in vitro and in vivo investigations. In the experiment, the researchers used many compounds, for example, 1-Phenyl-3,4-dihydroisoquinoline (cas: 52250-50-7SDS of cas: 52250-50-7).
1-Phenyl-3,4-dihydroisoquinoline (cas: 52250-50-7) belongs to isoquinoline derivatives. Being an analog of pyridine, isoquinoline is a weak base, with a pKa of 5.14. The discovery of chloroquine, the most well-known drug containing this stent, has helped bring about decades of malaria control and treatment.SDS of cas: 52250-50-7
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem